PD-1/PD-L pathway and autoimmunity

References

• Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996; 14: 233–258
   PubMed Web of Science ®Google Scholar
• Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998; 16: 111–135
   PubMed Web of Science ®Google Scholar
• Carreno BM, Collins M. The B7 family of ligands and its receptors: New pathways for costimulation and inhibition of immune responses. Annu Rev Immunol 2002; 20: 29–53
   PubMed Web of Science ®Google Scholar
• Okazaki T, Iwai Y, Honjo T. New regulatory co-receptors: Inducible co-stimulator and PD-1. Curr Opin Immunol 2002; 14: 779–782
   PubMed Web of Science ®Google Scholar
• Watanabe N, Garvieli M, Sedy JR, et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol, 4: 670–679
   PubMed Web of Science ®Google Scholar
• Chapoval AI, Ni L, Lau JS, et al. B7-H3: A costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol 2001; 2: 269–274
   PubMed Web of Science ®Google Scholar
• Suh WK, Gajewska BU, Okada H, et al. The ADP/ATP carrier as a mitochondrial auto-antigen—facts and perspectives. Nat Immunol 2003; 4: 899–906
   PubMed Web of Science ®Google Scholar
• Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1. a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992; 11: 3887–3895
   PubMed Web of Science ®Google Scholar
• Okazaki T, Maeda A, Nishimura H, et al. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci USA 2001; 98: 13866–13871
   PubMed Web of Science ®Google Scholar
• Ostrov DA, Shi W, Schwartz JC, et al. Structure of murine CTLA-4 and its role in modulating T cell responsiveness. Science 2000; 290: 816–819
   PubMed Web of Science ®Google Scholar
• Ikemizu S, Gilbert RJ, Fennelly JA, et al. Structure and dimerization of a soluble form of B7-1. Immunity 2000; 12: 51–60
   PubMed Web of Science ®Google Scholar
• Zhang X, Schwartz JC, Guo X, et al. Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity 2004; 20: 337–347
   PubMed Web of Science ®Google Scholar
• Agata Y, Kawasaki A, Nishimura H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996; 43: 129–139
   Google Scholar
• Zhong X, Bai C, Gao W, et al. Suppression of expression and function of negative immune regulator PD-1 by certain pattern recognition and cytokine receptor signals associated with immune system danger. Int Immunol 2004; 16: 1181–1188
   PubMed Web of Science ®Google Scholar
• Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192: 1027–1034
   PubMed Web of Science ®Google Scholar
• Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2: 261–268
   PubMed Web of Science ®Google Scholar
• Tseng SY, Otsuji M, Gorski K, et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 1111; 193: 839–846
   Google Scholar
• Liang SC, Latchman YE, Buhlmann JE, et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol 111; 33: 2706–2716
   Google Scholar
• Yamazaki T, Akiba H, Iwai H, et al. Expression of programmed death 1 ligands by murine T cells and APC. J Immunol 2002; 169: 5538–5545
   PubMed Web of Science ®Google Scholar
• Ishida M, Iwai Y, Tanaka Y, et al. Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol Lett 2002; 84: 57–62
   PubMed Web of Science ®Google Scholar
• Loke P, Allison JP. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci USA 2003; 100: 5536–5341
   Google Scholar
• Ansari MJ, Salama AD, Chitnis T, et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 2003; 198: 63–69
   PubMed Web of Science ®Google Scholar
• Salama AD, Chitnis T, Imitola J, et al. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med 2003; 198: 71–78
   PubMed Web of Science ®Google Scholar
• Kanai T, Totsuka Y, Uraushihara K, et al. Blockade of B7-H1 suppresses the development of chronic intestinal inflammation. J Immunol 2003; 171: 4156–4163
   PubMed Web of Science ®Google Scholar
• Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 2002; 8: 793–800
   PubMed Web of Science ®Google Scholar
• Strome SE, Dong H, Tamura H, et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res 2003; 63: 6501–6505
   PubMed Web of Science ®Google Scholar
• Wintterle S, Schreiner B, Mitsdoerffer M, et al. Expression of the B7-related molecule B7-H1 by glioma cells: A potential mechanism of immune paralysis. Cancer Res 2003; 63: 7462–7467
   PubMed Web of Science ®Google Scholar
• Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002; 99: 12293–12297
   PubMed Web of Science ®Google Scholar
• Chemnitz JM, Parry RV, Nichols KE, et al. SHP-1 and SHP-2 associate with immunoreceptor tyrosine based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 2004; 173: 945–954
   PubMed Web of Science ®Google Scholar
• Sidorenko SP, Clark EA. The dual-function CD150 receptor subfamily: The viral infection. Nat Immunol 2003; 4: 19–24
   PubMed Web of Science ®Google Scholar
• Dong H, Zhu G, Tamada K, et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med, 5: 1365–1369
   PubMed Web of Science ®Google Scholar
• Tamura H, Dong H, Zhu G, et al. B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function. Blood 2001; 97: 1809–1816
   PubMed Web of Science ®Google Scholar
• Shin T, Kennedy G, Gorski K, et al. Cooperative B7-1/2 (CD80/CD86) and B7-DC costimulation of CD4+ T cells independent of the PD-1 receptor. J Exp Med 2003; 198: 31–38
   PubMed Web of Science ®Google Scholar
• Latchman YE, Liang SC, Wu Y, et al. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci USA 2004; 101: 10691–10696
   PubMed Web of Science ®Google Scholar
• Nishimura H, Minato N, Nakano T, et al. Immunological studies on PD-1 deficient mice: Implication of PD-1 as a negative regulator for B cell responses. Int Immunol 1998; 10: 1563–1572
   PubMed Web of Science ®Google Scholar
• Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999; 11: 141–151
   PubMed Web of Science ®Google Scholar
• Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001; 291: 319–322
   PubMed Web of Science ®Google Scholar
• Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 1996; 93: 841–842
   PubMed Web of Science ®Google Scholar
• Cohn JN, Bristow MR, Chien KR, et al. Report of the National Heart, Lung, and Blood Institute Special Emphasis Panel on heart failure research. Circulation 1997; 95: 766–770
   PubMed Web of Science ®Google Scholar
• Matsumori A, Furukawa Y, Hasegawa K, et al. Epidemiologic and Clinical Characteristics of Cardiomyopathies in Japan. Circ J 2002; 66: 323–236
   PubMed Web of Science ®Google Scholar
• Solaro RJ, Rarick HM. Troponin and tropomyosin: Proteins that switch on and tune in the activity of cardiac myofilaments. Circ Res 1998; 83: 471–480
   PubMed Web of Science ®Google Scholar
• Okazaki T, Tanaka Y, Nishio R, et al. Autoantibodies against cardiac troponin I are responsible for the dilated cardiomyopathy in Pdcd1− / − mice. Nat Med 2003; 9: 1477–1483
   PubMed Web of Science ®Google Scholar
• Wallukat G, Reinke P, Dorffel WV, et al. Removal of autoantibodies in dilated cardiomyopathy by immunoadsorption. Int J Cardiol 1996; 54: 191–195
   PubMed Web of Science ®Google Scholar
• Dorffel WV, Wallukat G, Baumann G, et al. Immunoadsorption in dilated cardiomyopathy. Ther Apher 2000; 4: 235–238
   PubMedGoogle Scholar
• Felix SB, Staudt A, Dorffel WV, et al. Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: Three-month results from a randomized study. J Am Coll Cardiol 2000; 35: 1590–1598
   PubMed Web of Science ®Google Scholar
• Muller J, Wallukat G, Dandel M, et al. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation 2000; 101: 385–391
   PubMed Web of Science ®Google Scholar
• Felix SB, Staudt A, Landsberger M, et al. Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption. J Am Coll Cardiol 2002; 39: 646–652
   PubMed Web of Science ®Google Scholar
• Prokunina L, Casrillejo-Lopez C, Oberg F, et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 2002; 32: 666–669
   PubMed Web of Science ®Google Scholar
• Prokunina L, Gunnarsson I, Sturfelt G, et al. The systemic lupus erythematosus-associated PDCD1 polymorphism PD1.3A in lupus nephritis. Arthritis Rheum 2004; 50: 327–328
   PubMed Web of Science ®Google Scholar
• Nielsen C, Hansen D, Husby S, et al. Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes. Tissue Antigens 2003; 62: 492–497
   PubMed Web of Science ®Google Scholar
• Lin SC, Yen JH, Tsai JJ, et al. Association of a programmed death 1 gene polymorphism with the development of rheumatoid arthritis, but not systemic lupus erythematosus. Arthritis Rheum 2004; 50: 770–775
   PubMed Web of Science ®Google Scholar
• Helms C, Cao L, Krueger JG, et al. A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. Nat Genet 2003; 35: 349–356
   PubMed Web of Science ®Google Scholar
• Tokuhiro S, Yamada R, Chang X, et al. An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. Nat Genet 2003; 35: 341–348
   PubMed Web of Science ®Google Scholar